• Monarch Therapeutics, a pre-clinical adoptive drug conjugate company developing a lead program directed to metastatic ovarian cancer, is the winner of BioLabs Philadelphia’s coveted 2024 Golden Ticket competition
• The selected 2024 winner receives a year of free lab space and support at BioLabs Philadelphia, a world-class life science incubator at the heart of Philadelphia’s vibrant cell and gene therapy ecosystem
Philadelphia, PA, August 13, 2024 – BioLabs, the international pioneer in
premium laboratory coworking support, today announced the winner of the
BioLabs Philadelphia Golden Ticket 2024 as Monarch Therapeutics, an adoptive
drug conjugate company developing therapy candidates that treat solid tumors
using multi-targeting, adaptor-CAR technology to overcome solid tumor
heterogeneity and immunosuppressive environments.
Four high-potential life science startups were selected from a competitive applicant pool as Golden Ticket finalists. The finalists presented to the Golden Ticket Selection Committee — made up of senior leaders with entrepreneurial and scientific backgrounds from across the BioLabs network — on July 16th. After a series of excellent pitches, the Committee selected Monarch Therapeutics as the winner of this year’s competition. Monarch Therapeutics will commence laboratory work at BioLabs Philadelphia, located in the growing biotech hub of the Curtis in center city, this fall.
Monarch Therapeutics is developing a drug conjugate adaptor-CAR platform developed at the University of Pittsburgh that enables the flexible targeting of multiple tumor antigens with drug conjugates to deliver cytotoxic T-cells to tumors. Monarch Therapeutics’ vision is to develop a catalog of therapeutic conjugates that leverage this core platform technology to provide patients and clinicians with flexible therapy strategies that enable personalized multitargeting solutions for solid tumors. Monarch Therapeutics’ lead program is a multi-target program directed to metastatic ovarian cancer that is entering IND enabling studies in the coming months.
“We are honored to have been selected as the winner of the BioLabs Philadelphia Golden Ticket 2024 award,” said Monarch CEO Christopher Potts. “We will use this award to continue building our platform and therapy candidates and advance on our vision to enable personalized multi targeting therapies for difficult to treat diseases. Joining the BioLabs network will enable us to leverage the BioLabs and Philadelphia ecosystem to grow to our full potential. Monarch Therapeutics is led by a team that is spread throughout the surrounding region including New Jersey, Ohio, and Maryland and is developing technology from the University of Pittsburgh. Philadelphia offers a key base of operations for Monarch as a regional talent hub with a track record of leadership in advanced therapeutics. We look forward to getting to work in Philadelphia.”
Over 50 Golden Tickets have been awarded across the BioLabs network since the program’s inception, supporting innovative entrepreneurs from across the US and Europe. Winners of the Golden Ticket receive one year of membership and a dedicated laboratory bench at a BioLabs network site, helping them to reach their goals faster and move cutting-edge science closer to the clinic.
About BioLabs
Biolabs’ mission is to empower entrepreneurs and drive life science innovation worldwide. BioLabs’ comprehensive innovation support platform provides entrepreneurs access to premium, fully equipped coworking lab and office facilities, extensive educational programming, a supportive community, and connections to a global network of fellow entrepreneurs, collaborators, and capital partners. Currently operating in 16 locations across the US, Europe and Japan, BioLabs accelerates the pace of innovation commercialization by enabling entrepreneurs to focus on science, not operations.
About Monarch Therapeutics
Monarch Therapeutics is a pre-clinical, early-stage company that develops adoptive drug conjugates for solid tumors and autoimmune indications. Monarch Therapeutics has differentiated platform technology that enables the development of universal, tunable, and scalable adaptor-CAR conjugate therapies that can target multiple tumor antigens.
For more information visit www.monarchtherapeutics.com and follow them on LinkedIn.
Contact
For Monarch Therapeutics:
Christopher Potts
CEO
For BioLabs:
Melina Blees, PhD
Site Head, BioLabs Philadelphia
Comments